Nature interview 2024
paperCredibility Rating
Gold standard. Rigorous peer review, high editorial standards, and strong institutional reputation.
Rating inherited from publication venue: Nature
This URL resolves to the Nature magazine homepage rather than a specific AI safety paper or interview; the title 'Nature interview 2024' does not match the content, and the resource should be updated with a direct article URL for meaningful reference.
Metadata
Summary
This is the homepage of Nature, a leading multidisciplinary scientific journal, displaying current news and research articles. The visible content includes stories on AI's influence on human expression, China's AI ambitions, and AI-driven memory shortages in labs, alongside biology and neuroscience research. No specific AI safety paper or interview is identifiable from the content provided.
Key Points
- •Article highlighted: 'AI can same-ify human expression' — LLM outputs may shape text and thoughts of human users
- •News item: China's five-year plan reaffirms goal to be world leaders in AI and technology
- •'RAMmageddon': AI-driven memory shortages are reportedly impacting scientific research labs
- •Homepage reflects broad science coverage; no specific 'Nature interview 2024' AI safety content is identifiable from the scraped text
- •Content appears to be from March 2026 issue, not 2024 as the title suggests
Cited by 4 pages
| Page | Type | Quality |
|---|---|---|
| AGI Timeline | Concept | 59.0 |
| AI Risk Warning Signs Model | Analysis | 70.0 |
| AI Disinformation | Risk | 54.0 |
| AI Knowledge Monopoly | Risk | 50.0 |
Cached Content Preview
Nature
Skip to main content
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Advertisement
One woman, three autoimmune diseases: CAR-T therapy vanquishes ultra-rare disease trio
Fourteen months after treatment with engineered immune cells, the recipient has no symptoms and doesn’t need to take medication.
Featured Content
I was with Artemis II’s scientists during the Moon fly-by. Here’s what I saw
Nature correspondent Alexandra Witze describes the joy and tension at mission control in Houston.
Alexandra Witze
Muse 09 Apr 2026
Female mice grow testes after this single DNA tweak
Small changes in the non-coding part of the genome have a key role in sex determination.
Rachel Fieldhouse
News 09 Apr 2026
Biodiversity resilience in a tropical rainforest
Assessment of how 16 taxonomic groups in a lowland tropical forest resist and recover from anthropogenic disturbance shows the potential of protecting naturally regenerating secondary forests to reverse biodiversity losses.
Timo Metz
Nina Farwig
Nico Blüthgen
Article Open Access 08 Apr 2026
Daily briefing: AI spread information about an obviously made-up disease
AI chatbots informed users of the symptoms of ‘bixonimania’ after scientists published just two fake preprints. Plus, different psychedelics work in surprisingly similar ways and an influential report on the economic cost of climate change revisited.
Flora Graham
Nature Briefing 08 Apr 2026
Contents
Subscribe
Current Issue 09 Apr 2026
Advertisement
News & Comment
One woman, three autoimmune diseases: CAR-T therapy vanquishes ultra-rare disease trio
Fourteen months after treatment with engineered immune cells, the recipient has no symptoms and doesn’t need to take medication.
Edward Chen
News 09 Apr 2026
... (truncated, 12 KB total)76ad6e98c47f6ff5 | Stable ID: sid_m3O0MpjCMu